Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF, Longo DL. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi:10.1056/NEJMra170341328854088
   PubMed Web of Science ®Google Scholar
• Shlomi D, Ben-Avi R, Balmor GR, Onn A, Peled N. Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J. 2014;44(1):217–238. doi:10.1183/09031936.0016451324525442
   PubMed Web of Science ®Google Scholar
• Hu J, Qian GS, Bai CX. Lung Cancer Study Group of Chinese Thoracic S, Chinese Alliance Against Lung Cancer Expert G. Chinese consensus on early diagnosis of primary lung cancer (2014 version). Cancer. 2015;121(Suppl 17):3157–3164. doi:10.1002/cncr.2957126331822
   PubMedGoogle Scholar
• Tammemagi MC, Lam S. Screening for lung cancer using low dose computed tomography. BMJ. 2014;348:g2253. doi:10.1136/bmj.g225324865600
   PubMedGoogle Scholar
• He Y, Zhang X, Wang L, et al. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing. Int J Oncol. 2016;49(6):2351–2358. doi:10.3892/ijo.2016.373127748796
   PubMed Web of Science ®Google Scholar
• Birse CE, Lagier RJ, FitzHugh W, et al. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015;12(1):18. doi:10.1186/s12014-015-9090-926279647
   PubMedGoogle Scholar
• Matikas A, Syrigos KN, Agelaki S. Circulating biomarkers in non-small-cell lung cancer: current status and future challenges. Clin Lung Cancer. 2016;17(6):507–516. doi:10.1016/j.cllc.2016.05.02127373516
   PubMed Web of Science ®Google Scholar
• Engelhardt KE, Feinglass JM, DeCamp MM, Bilimoria KY, Odell DD. Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: a time-trend analysis of the National Cancer Data Base. J Thorac Cardiovasc Surg. 2018;156(3):1233–1246 e1231. doi:10.1016/j.jtcvs.2018.03.17430119287
   PubMed Web of Science ®Google Scholar
• Fiorelli A, Accardo M, Carelli E, Angioletti D, Santini M, Di Domenico M. Circulating tumor cells in diagnosing lung cancer: clinical and morphologic analysis. Ann Thorac Surg. 2015;99(6):1899–1905. doi:10.1016/j.athoracsur.2014.11.04925678504
   PubMed Web of Science ®Google Scholar
• Yu N, Zhou J, Cui F, Tang X. Circulating tumor cells in lung cancer: detection methods and clinical applications. Lung. 2015;193(2):157–171. doi:10.1007/s00408-015-9697-725690734
   PubMed Web of Science ®Google Scholar
• Zhang W, Xia W, Lv Z, Ni C, Xin Y, Yang L. Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes? Cell Physiol Biochem. 2017;41(2):755–768. doi:10.1159/00045873628214887
   PubMedGoogle Scholar
• Coumans FA, Ligthart ST, Uhr JW, Terstappen LW. Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 2012;18(20):5711–5718. doi:10.1158/1078-0432.CCR-12-158523014524
   PubMed Web of Science ®Google Scholar
• Saucedo-Zeni N, Mewes S, Niestroj R, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–1250. doi:10.3892/ijo.2012.155722825490
   PubMed Web of Science ®Google Scholar
• He Y, Shi J, Shi G, et al. Using the new cellcollector to capture circulating tumor cells from blood in different groups of pulmonary disease: a Cohort study. Sci Rep. 2017;7(1):9542. doi:10.1038/s41598-017-09284-028842574
   PubMedGoogle Scholar
• Gorges TM, Penkalla N, Schalk T, et al. Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells. Clin Cancer Res. 2016;22(9):2197–2206. doi:10.1158/1078-0432.CCR-15-141626667488
   PubMed Web of Science ®Google Scholar
• Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016;11(7):964–975. doi:10.1016/j.jtho.2016.04.01427117833
   PubMed Web of Science ®Google Scholar
• Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One. 2014;9(8):e103883. doi:10.1371/journal.pone.010388325137181
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–484. doi:10.1038/nrclinonc.2013.11023836314
   PubMed Web of Science ®Google Scholar
• He J, Tan W, Ma J. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. Future Oncol. 2017;13(9):787–797. doi:10.2217/fon-2016-042728073294
   PubMed Web of Science ®Google Scholar
• Breitenbuecher F, Hoffarth S, Worm K, et al. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One. 2014;9(1):e85350. doi:10.1371/journal.pone.008535024465542
   PubMed Web of Science ®Google Scholar
• Fortune JB, Feustel P. Effect of patient position on size and location of the subclavian vein for percutaneous puncture. Arch Surg. 2003;138(9):996–1000; discussion 1001. doi:10.1001/archsurg.138.9.996
   PubMedGoogle Scholar
• Hanssen A, Loges S, Pantel K, Wikman H. Detection of circulating tumor cells in non-small cell lung cancer. Front Oncol. 2015;5:207. doi:10.3389/fonc.2015.0020726442219
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010. doi:10.1016/S0140-6736(14)62038-925467588
   PubMed Web of Science ®Google Scholar
• Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31(3):365–372. doi:10.1200/JCO.2012.44.290523248251
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–584. doi:10.1126/science.122852223372014
   PubMed Web of Science ®Google Scholar
• Xie Z, Gao X, Cheng K, Yu L. Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period. Oncol Lett. 2017;14(5):5825–5830. doi:10.3892/ol.2017.691029113213
   PubMed Web of Science ®Google Scholar
• Chemi F, Rothwell DG, McGranahan N, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019;25(10):1534–1539. doi:10.1038/s41591-019-0593-131591595
   PubMed Web of Science ®Google Scholar
• Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003. doi:10.1200/JCO.2012.45.609523610105
   PubMed Web of Science ®Google Scholar
• Gialeli C, Nikitovic D, Kletsas D, Theocharis AD, Tzanakakis GN, Karamanos NK. PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts. Curr Pharm Des. 2014;20(17):2843–2848. doi:10.2174/1381612811319999059223944365
   PubMed Web of Science ®Google Scholar
• Kang HG, Lee SY, Jeon HS, et al. A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females. J Thorac Oncol. 2014;9(11):1647–1655. doi:10.1097/JTO.000000000000031025144241
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. doi:10.1126/scitranslmed.3001451
   PubMed Web of Science ®Google Scholar
• Tran TN, Selinger CI, Kohonen-Corish MR, et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 2013;81(3):462–467. doi:10.1016/j.lungcan.2013.05.01523806793
   PubMed Web of Science ®Google Scholar
• Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–1122. doi:10.1016/j.cell.2014.07.01325171411
   PubMed Web of Science ®Google Scholar
• Hong Y, Fang F, Zhang Q. Circulating tumor cell clusters: what we know and what we expect (Review). Int J Oncol. 2016;49(6):2206–2216. doi:10.3892/ijo.2016.374727779656
   PubMed Web of Science ®Google Scholar
• Yuan CL, Li H, Zhu L, Liu Z, Zhou J, Shu Y. Aberrant expression of long noncoding RNA PVT1 and its diagnostic and prognostic significance in patients with gastric cancer. Neoplasma. 2016;63(3):442–449. doi:10.4149/314_150825N4526925791
   PubMed Web of Science ®Google Scholar
• Rodrigues P, Vanharanta S. Circulating tumor cells: come together, right now, over metastasis. Cancer Discov. 2019;9(1):22–24. doi:10.1158/2159-8290.CD-18-128530626605
   PubMed Web of Science ®Google Scholar
• Liu X, Taftaf R, Kawaguchi M, et al. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 2019;9(1):96–113. doi:10.1158/2159-8290.CD-18-006530361447
   PubMed Web of Science ®Google Scholar
• Wang G, Benasutti H, Jones JF, et al. Isolation of breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces. 2018;161:200–209. doi:10.1016/j.colsurfb.2017.10.06029080504
   PubMed Web of Science ®Google Scholar
• Choi JW, Kim JK, Yang YJ, Kim P, Yoon KH, Yun SH. Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells. Cancer Res. 2015;75(21):4474–4482. doi:10.1158/0008-5472.CAN-15-068426527605
   PubMed Web of Science ®Google Scholar
• Divella R, Daniele A, Abbate I, et al. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer. Cancer Causes Control. 2014;25(11):1531–1541. doi:10.1007/s10552-014-0457-425135616
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. doi:10.1158/1535-7163.MCT-14-098325695955
   PubMed Web of Science ®Google Scholar
• Tang Y, Fang W, Zhang Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 2015;6(16):14209–14219. doi:10.18632/oncotarget.v6i1625895031
   PubMedGoogle Scholar
• Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014;7:357–365. doi:10.2147/PGPM.S5316325484597
   PubMedGoogle Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:10.1056/NEJMoa150182425891174
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa151066526406148
   PubMed Web of Science ®Google Scholar
• Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39–46. doi:10.1093/intimm/dxu09525323844
   PubMed Web of Science ®Google Scholar
• Nicolazzo C, Raimondi C, Mancini M, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726. doi:10.1038/srep3172627553175
   PubMed Web of Science ®Google Scholar
• Boffa DJ, Graf RP, Salazar MC, et al. Cellular Expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival. Cancer Epidemiol Biomarkers Prev. 2017;26(7):1139–1145. doi:10.1158/1055-9965.EPI-17-012028446544
   PubMed Web of Science ®Google Scholar
• Ilie M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol. 2018;29(1):193–199. doi:10.1093/annonc/mdx63629361135
   PubMed Web of Science ®Google Scholar
• Guibert N, Delaunay M, Lusque A, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112. doi:10.1016/j.lungcan.2018.04.00129748004
   PubMed Web of Science ®Google Scholar